|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 251 18th Street S |
Address2 | 8th Floor |
| City | Arlington |
State | VA |
Zip Code | 22202 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 57737-12
|
||||||||
|
6. House ID# 352510000
|
||||||||
| TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Dave Adler |
Date | 1/20/2021 9:08:08 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
The Resident Education Deferred Interest Act (HR 1554)
FY2020 LHHS Appropriations bill-funding for NIH/NCI
Access to radioactive isotopes
Support to ensure that patient care advances in biomedical research impacting patient care are not compromised by any policies imposed on the
medical use and research applications of cesium chloride.
Support for NRC Commissioner nominee to have medical background.
Support patient choice in treatment options by closing the in-office ancillary services exception to the Stark Law for radiation oncology services;
Protecting Integrity in Medicare Act (H.R. 2143)
Radiation Oncology reimbursement
Radiation Oncology safety
Cancer Moonshot Initiative
Supplemental Appropriations for Disaster Relief for Puerto Rico
Legislation to increase transparency in the prior authorization process
Efforts to educate legislators about un-intended consequences associated with rate setting for health care services
HR 1966 Henrietta Lacks Enhancing Cancer Research Act of 2019
HR3107 Improving Seniors timely access to care act
Curb surprise billing for patients
preserve current training and experience requirements for radiopharmaceuticals
H.R.748 CARES Act
S.3548 CARES Act
H.R.6201 Families First Coronavirus Response Act
H.R.6074 Coronavirus Preparedness and Response
Supplemental Appropriations Act, 2020
Economic relief for 501c6 organizations
HR 5924 - Encourages specialty medicine physicians to serve in rural communities experiencing shortages of specialists.
H.R.7255 - Coronavirus Health Care Worker Wellness Act of 2020- To authorize the Secretary of Health and Human Services to award grants to health care providers to establish or expand programs dedicated to promoting mental wellness among their health care workers, including contractors, on the front lines of the SARS-CoV-2 pandemic, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Food & Drug Administration (FDA), Nuclear Regulatory Commission (NRC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dave |
Adler |
|
|
|
Cynthia |
Tomlinson |
|
|
|
Margarita |
Valdez |
|
|
|
Anne |
Hubbard |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR 913, Clinical Treatment Act
Local Coverage Determinations Clarification Act
Oppose restrictive prior authorization practices.
S.2425-Patient Access and Medicare Protection Act (PAMPA) implementation.
Support for legislation to ensure patient safety and preserve the integrity of the Medicare program by ending abuses of the physician self-referral law.
for radiation therapy services; Promoting Integrity in Medicare Act (H.R. 2143)
Support for structural changes that lead to delivering high-quality care for patients while increasing efficiencies and promoting Medicare.
sustainability; oppose radiation oncology benefit managers.
Support for ensuring radiation oncologists participation in the Medicare electronic health record incentive program.
Support for reforming the way Medicare pays for radiation oncology services by tying payments to quality and value.
Implementation of H.R. 2, the Medicare Access and CHIP Reauthorization Act of 2015
Support for reforms to the CMMI Proposed Radiation Oncology Alternative Payment Model
S.3230 - TA SUPPORT Act to ensure that small and rural physician practices participating in Medicares new Merit-Based Incentive Payment System (MIPS) have access to the technical assistance.
Support for waiving budget neutrality adjustments associated with evaluation and management code changes.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dave |
Adler |
|
|
|
Cynthia |
Tomlinson |
|
|
|
Margarita |
Valdez |
|
|
|
Anne |
Hubbard |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Support for protecting access to medical isotopes used in cancer treatments such as brachytherapy and stereotactic radio surgery.
Support access to radioactive isotopes.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Nuclear Regulatory Commission (NRC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dave |
Adler |
|
|
|
Cynthia |
Tomlinson |
|
|
|
Margarita |
Valdez |
|
|
|
Anne |
Hubbard |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Support legislation to increase the budget for the National Institutes of Health, National Cancer Institute and the Centers for Disease Control and
Prevention for fiscal year 2020.
Support for increased funding for radiation therapy cooperative groups within the National Cancer Institute.
Support for the National Institutes of Health to recognize radiation oncology as an individual specialty in reporting systems to create more
transparency of federal appropriations.
Ensure that radiological materials used for the diagnosis and treatment of patients are secured and access to care preserved.
Cancer Moonshot Initiative
S. 3203 - Therapeutic Medical Physicists Pay Cap Legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dave |
Adler |
|
|
|
Cynthia |
Tomlinson |
|
|
|
Margarita |
Valdez |
|
|
|
Anne |
Hubbard |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |